Sos ML et al. using a panel of NSCLC cell lines, confirmed that tumors with activating mutations in RTKs present high dependence on PI3K signaling and mutations in the RAS/RAF pathway is strongly correlated with MAPK signaling [99]. The gene discussed is PIK3CD; the disease is non-small cell lung carcinoma.